Reuters: Judge Orders Merck Documents on Anti-Baldness Drug Propecia Unsealed
A U.S. judge granted Reuters’ request to unseal Merck & Co documents related to lawsuits over Propecia, prioritizing public access.
Plaintiffs claimed Merck didn’t fully disclose sexual dysfunction risks with Propecia. Sixteen months after Reuters’ motion, Judge Peggy Kuo ruled Merck’s arguments too weak to override access rights. Merck stated it interacted transparently with regulators and maintains Propecia is safe and effective.
In 2012, over 1,100 Propecia-related lawsuits were consolidated, with most settled in 2018 for $4.3 million. Judge Kuo disagreed with Merck’s argument that settled cases shouldn’t unseal documents.
Read the full story on Reuters: Judge Orders Merck Documents on Anti-Baldness Drug Propecia Unsealed
Learn more about PFS & PSSD
What is Post-Finasteride Syndrome?
PFS (Post-Finasteride Syndrome) is a complex and life-altering condition caused by the drug Finasteride (also marketed as Propecia) and other 5ar inhibitors. It affects physical, mental, and sexual health, leaving patients to suffer without adequate support, recognition or treatment.
What is Post-SSRI Sexual Dysfunction?
PSSD (Post-SSRI Sexual Dysfunction) is a serious and debilitating condition associated with the use of selective serotonin reuptake inhibitors (SSRIs) and similar drugs. It affects mental, physical, and sexual well-being, leaving many patients to suffer without sufficient support, recognition, or effective treatment.
